copy of the oral presentation to Lynne Johnson, Health Insurance Specialist, Division of Partnership Development, Center for Beneficiary Choices, Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Mail stop S2–23–05, Baltimore, MD 21244–1850 or by email at *Lynne.Johnson@cms.hhs.gov,* no later than 12 noon, e.d.t., September 20, 2005. The number of oral presentations may be limited by the time available. Individuals not wishing to make a presentation may submit written comments to Ms. Johnson by 12 noon, (e.d.t.), September 20, 2005. The meeting is open to the public, but attendance is limited to the space available.

Special Accommodation: Individuals requiring sign language interpretation or other special accommodations should contact Ms. Johnson at least 15 days before the meeting.

Authority: Sec. 222 of the Public Health Service Act (42 U.S.C. 217a) and sec. 10(a) of Pub. L. 92–463 (5 U.S.C. App. 2, sec. 10(a) and 41 CFR 102–3).

(Catalog of Federal Domestic Assistance Program No. 93.733, Medicare—Hospital Insurance Program; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: August 19, 2005.

Mark B. McClellan,

Administrator, Centers for Medicare & Medicaid Services.

[FR Doc. 05–16800 Filed 8–25–05; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Temporary Assistance for Needy Families (TANF) State Plan Guidance.

OMB No.: 0970–0145.

Description: The State plan is a mandatory statement submitted to the Secretary of the Department of Health and Human Services by the State. It consists of an outline of how the State's TANF program will be administered and operated and certain required certifications by the State's Chief Executive Officer. Its submittal triggers the State's family assistance grant funding and it is used to provide the public with information about the program. If a State makes changes in its program, it must submit a State plan amendment.

Respondents: The 50 States, the District of Columbia, Guam, Puerto Rico and the Virgin Islands.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Temporary Assistance for Needy Families (TANF) State Plan Guidance	54	0.5	33	891

Estimated Total Annual Burden Hours: 891

Additional Information

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: *grjohnson@acf.hhs.gov.*

OMB Comment

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Attn: Desk Officer for ACF, E-mail address: *Katherine_T._Astrich@omb.eop.gov.*

Dated: August 23, 2005.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 05–17008 Filed 8–25–05; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2005N–0149]

Animal Drugs, Feeds, and Related Products; Withdrawal of Approval of New Animal Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 16 new animal drug applications (NADAs) and 1 abbreviated NADA (ANADA) because the products are no longer manufactured or marketed. In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to remove portions reflecting approval of the NADAs.

DATES: Withdrawal of approval is effective September 6, 2005.

FOR FURTHER INFORMATION CONTACT: Pamela K. Esposito, Center for Veterinary Medicine (HFV–210), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301–827–7818, or e-mail: *pesposit@cvm.fda.gov.*

SUPPLEMENTARY INFORMATION: The following sponsors have requested that FDA withdraw approval of the 16 NADAs and 1 ANADA listed in table 1 of this document because the products are no longer manufactured or marketed:

TABLE 1.

Sponsor	NADA Number, Product (Drug)	21 CFR Section Affected, (Sponsor Drug Labeler Code)
Abbott Laboratories, North Chicago, IL 60064	NADA 99–568, FURANACE Caps (nifurpirinol)	529.1526 (000074)
Biocraft Laboratories, Inc., 92 Route 46, Elmwood Park, NJ 07407	NADA 140–889, DERM–OTIC Ointment (neomycin sulfate, nystatin, thiostrepton, triamcinolone acetonide)	524.1600a (000332)
First Priority, Inc., 1585 Todd Farm Dr., Elgin, IL 60123	NADA 48–646, THERAZONE Injection (phenylbutazone)	522.1720 (058829)
Happy Jack, Inc., Snow Hill, NC 28580	NADA 121–556, Selenium Sulfide Suspension (selenium disulfide) NADA 121–723, Nitrofurazone Dressing NADA 125–137, FILARICIDE Capsules (diethylcarbamazine citrate)	524.2101 (023851) 524.1580b (023851) 520.622d (023851)
IMPAX Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544	NADA 92–151, N-Butyl Chloride Canine Worming Caps NADA 65–065, Tetracycline HCl Caps NADA 138–900, Dichlorophene/Toluene	520.260 (000115) 520.2345a (000115) 520.580 (000115)
Jorgensen Laboratories, Inc., 1450 North Van Buren Ave., Loveland, CO 80538	NADA 10–481, SUREJETS (salacylic acid)	529.2090 (048087)
Pliva d.d., Ulica grada Vukovara 49, 10000 Zagreb, Croatia	ANADA, 200–232, GEOMYCIN 200 Injection (oxytetracycline)	522.1660a (011722)
Purina Mills, Inc., P.O. Box 66812, St. Louis, MO 63166-6812	NADA 65–113 AUREO Sulfa Soluble Powder (chlortetracycline/sulfamethazine)	N/A (017800)
Roche Vitamins, Inc., 45 Waterview Blvd., Parsippany, NJ 07054–1298	NADA 140–848, VETEEZE Injection (diazepam)	522.575 (063238)
Teva Pharmaceuticals USA, 650 Cathill Rd., Sellersville, PA 18960	NADA 131–806, Furosemide Tablets	520.1010 (000093)
Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137	NADA 10–886, Purina Liquid Wormer (piperazine citrate)	N/A (051311)
Wyeth Laboratories, Division of American Home Products Corp., P.O. Box 8299, Philadelphia, PA 19101	NADA 10–782, SPARINE Injection (promazine) NADA 55–008, BICILLIN Fortified (penicillin G benzathine and penicillin G procaine)	522.1962 (000008) 522.1696a (000008)

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10), redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADAs 10–481, 10–782, 10–886, 48–646, 55–008, 65–065, 65–113, 99–568, 121–556, 121–723, 125–137, 131–806, 138–900, 140–848, 140–889, and ANADA 200–232, and all supplements and amendments thereto, is hereby withdrawn, effective September 6, 2005.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Dated: July 5, 2005.

Linda Tollefson,

Acting Director, Center for Veterinary Medicine.

[FR Doc. 05–16994 Filed 8–25–05; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Establishment

Pursuant to the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), the Director, National Institutes of Health (NIH), announces the establishment of the National Commission on Digestive Diseases (Commission).

This Commission shall conduct an overview of the state-of-the-science in the field of digestive diseases research and develop a long-range plan for digestive diseases research consistent with the research mission of NIH. The overall plan will focus on the goal of improving the health of the nation through digestive diseases research and will include specific objectives and goals and a recommended time line for their implementation. Recommendations shall be made to the Director, NIH and to Congress.

The Commission shall be composed of 16 members appointed by the Director, NIH and 18 nonvoting ex officio members. Of the appointed members, who shall have a broad diversity of scientific and professional experience, 12 shall be knowledgeable about digestive diseases as members of academic or medical research and practice communities involved in digestive diseases research, including